Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/89BIO-INC-74010954/news/89Bio-gibt-zusatzliche-Daten-aus-der-Phase-2B-Studie-Enliven-mit-Pegozafermin-bei-Patienten-mit-kom-45344868/?utm_source=whatsapp&utm_medium=social&utm_campaign=share